Why were you pushing such high doses of reta if you’re an ectomorph?
All GLP1s can cause it. I’ve experienced it with doses of tirzepatide higher than 10mg. It is transient and not that annoying. Sort of feels like sunburn.
1 Like
Thanks for the video! I asked my PCP a second time and she said yes. So I can get the prescription version of tirzepatide in vials and self inject. I start this week.
1 Like
Weird theory, but I wonder if what you’re feeling is accelerated burning of junk and fat cells in your skin.
To my knowledge it’s pretty encompassing in its health effects besides the weight issue, in terms of metabolic improvements, protection of organs, against cognitive decline, cancer etc.
I should also say, I wasn’t blessed with the best metabolism as a ecotomorph. While it’s true I’m a 6’3 160 stick now, I was the definition of skinny fat and had the frame of a lot of visceral fat at 6’3/200 while starting (admittedly, not the best diet/lifestyle). Despite weight lifting program, never could gain much muscle
1 Like
For any of you that have used both Tirzepatide and Retatrutide, did you notice a different in resting heart rate between the two?
I think this has been beaten to death previously but for me not much of difference, went up about 10-15 and stayed there no matter which I did. I stopped them cold (all peps) including GLp1’s and HR is trending down again, albeit slowly, down about 5-6 in last 6-7 months.
Having said that I’ve read people saying that they had more increases from reta than tirze, and some people claiming very little increases from either (i.e. 3-4 points). As it has been noted GLP1’s seem to have big differences from person to person (the weight loss, and side effects), more so than with other meds.
Topline data for TRIUMPH-1 trial: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
At 80 weeks:
- 4 mg dose lost an average of 47.2 lbs (19.0% of their starting body weight)
- 9 mg dose lost an average of 64.4 lbs (25.9% of starting BW)
- 12 mg dose lost an average of 70.3 lbs (28.3% of starting body weight).
So if you’re morbidly obese, you have a legitimate alternative to bariatric surgery, with added bonus of improved metabolic markers.
First part of the study lasted 80 weeks, and there was still no plateau. They did an extension to 104 weeks for a subset of the participants where they escalated their dose to 12mg, and weight loss continued. That’s potentially 2 years of weight loss with no plateau. Much better than tirzepatide, which showed plateau around 48 weeks on average.
4 Likes
1 Like
Second week at 12mg of reta!
Appetite supression is really mild I can still eat 2000kcal (on a 3000kcal maintenance).
HR is almost the same. Skin sensations are really down but it weirdly depends on the day.
Here a 1 month difference. A few kilos of fat to lose and I’ll be good. I don’t plan to lower the dose, I want to downsize a bit (I was up to 92kg for 1m72, cardio was getting harder and moving was difficult for some movements like putting my socks…
2 Likes
How is the sleep apnea going?
The CPAP is a game changer, I no longer fall asleep everywhere and I feel rested when I wake up.
I average 9h of sleep.
Last time the technician was here the count of sleep apnea has been divided by 65, I was doing 2 events an hour instead of 128.
BP and HR and down.
1 Like
Nice. Better to have it under control but hopefully you can get rid of the sleep apnea entirely and not need the machine. Machine drove me crazy.
My whole X feed is discussing the Retatrutide phase 3 results. Seems to be what everyone is talking about right now.
4 Likes
I wonder if the other metabolic/anti inflammation etc health affects are just as dose dependent… thats why I was aiming to get up there in dosage
Apparently there are tests to measure glp-1 in plasma which I may need. Aside from being an ectomorph, I think a possible reason I’m responding so well in terms of weight loss/side effects to a lower dosage is because of the other supplements I’m taking that either are additive or synergistic to the process. Not only the copies glycine I take, but apparently Telmisartan (and I take 80 mg) acts synergistic with it and who knows what else in a persons lengthy stack could influence the process
I suspect not, if someone responds very well to the drug. But metabolic benefits are things you can easily measure with blood tests to validate your hypothesis in your specific case.
Both increased RHR but not in a concerning way:
Tirz at 14mg/week - RHR up 4-5 from base
Reta at 12mg/week - RHR up 6-8 from base.
Base: 61 - Tirz: 65 - Reta: 69
2 Likes
I believe these tests for specific blood serum GLP or similar are proprietary to EL and Novo.
But the end goals are different and include biomarkers you can test:
Metabolic Health & Inflammation Panel
| Marker Category | Common Name | Exact Labcorp Test Name | Labcorp Test Code |
|---|---|---|---|
| Blood Sugar & Insulin | Fasting Glucose | Glucose, Serum (or as part of a Comprehensive Metabolic Panel) | 001032 (or 001400) |
| Blood Sugar & Insulin | Hemoglobin A1c | Hemoglobin (Hb) A1c | 001453 |
| Blood Sugar & Insulin | Fasting Insulin | Insulin | 004333 |
| Lipids & Cardiovascular | Standard Lipids | Lipid Panel | 303756 |
| Lipids & Cardiovascular | Apolipoprotein B | Lipid Panel with Apolipoprotein B (ApoB) | 123544 |
| Inflammation | hs-CRP | C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment) | 120766 |
| Inflammation | Homocysteine | Homocyst(e)ine | 706994 |
3 Likes
And if bothering to test those, consider also testing common markers with valuable info:
Core Companion Panel Additions
| Marker Category | Common Name | Exact Labcorp Test Name | Labcorp Test Code |
|---|---|---|---|
| Foundational Health | CBC with Diff | CBC With Differential/Platelet | 005009 |
| Foundational Health | CMP | Comprehensive Metabolic Panel (14) | 001400 |
| Metabolic Control | TSH (Thyroid) | Thyroid-stimulating Hormone (TSH) | 004259 |
| Inflammation / Storage | Ferritin | Ferritin | 004598 |
| Metabolic / Gout Risk | Uric Acid | Uric Acid | 001057 |
| Hormone / Immune | Vitamin D | Vitamin D, 25-Hydroxy | 081950 |
2 Likes
New triple agonist GLP1 hitting the same things but likely different ratio of what it is hitting. I suspect more glucagon.
Novo Nordisk’s CEO believes its triple agonist UBT251 could ultimately outperform Eli Lilly’s retatrutide, though the evidence is still early. Retatrutide is already in late-stage trials and has shown about 28–30% weight loss over 1.5–2 years, which analysts describe as “unprecedented,” but with some tolerability concerns. UBT251 is still in phase II with about 20% weight loss at 24 weeks in early data. At present, retatrutide has much stronger clinical backing, while UBT251 is a promising but unproven challenger.
3 Likes